German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
This Is What Whales Are Betting On Bristol-Myers Squibb
Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb. Looking…
Bristol-Myers Squibb’s Options Frenzy: What You Need to Know
Investors with a lot of money to spend have taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And…
Smart Money Is Betting Big In BMY Options
Investors with a lot of money to spend have taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And…
FDA Approves Geron’s First Commercial Drug, Competes With Bristol Myers Squibb’s Blood Cancer Drug
FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia Geron's first commercial treatment targets a market potential of $1.2 billion.
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was well-tolerated.
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC.
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates.
FDA Expands Approval For Bristol Myers Squibb’s Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication.